DirectRx pharmacy distributing COPD therapy Ohtuvayre in US
DirectRx, a specialty pharmacy, is now part of the exclusive U.S. network distributing Ohtuvayre (ensifentrine), a newly approved COPD therapy. Ohtuvayre, priced at $2,950 per month, is the first new COPD therapy in over two decades, offering both anti-inflammatory and airway-widening effects without the side effects of inhaled corticosteroids. It was approved based on Phase 3 trial data showing significant improvements in lung function and reduced exacerbation rates.
Related Clinical Trials
Highlighted Terms
Related News
DirectRx, a specialty pharmacy, is now part of the exclusive U.S. network distributing Ohtuvayre (ensifentrine), a newly approved COPD therapy. Ohtuvayre, priced at $2,950 per month, is the first new COPD therapy in over two decades, offering both anti-inflammatory and airway-widening effects without the side effects of inhaled corticosteroids. It was approved based on Phase 3 trial data showing significant improvements in lung function and reduced exacerbation rates.